Halberd Corp
OTC:HALB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shandong Yanggu Huatai Chemical Co Ltd
SZSE:300121
|
CN |
Halberd Corp
Capital Expenditures
Halberd Corp
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Halberd Corp
OTC:HALB
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$1.9B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-12%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Capital Expenditures
-$58.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-16%
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
Capital Expenditures
-$16m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Capital Expenditures
-$526m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-55%
|
CAGR 10-Years
-27%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Capital Expenditures
-$202m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
Halberd Corp
Glance View
Halberd Corp. is a development stage company, researches and develops antibodies and devices for the prevention, detection, and treatment of Covid-19 through laboratory, hospital, and clinical trials. The company is headquartered in Jackson Center, Pennsylvania. The company went IPO on 2009-06-12. The firm is a research-based company that intends to discover and develop medical treatments for a range of diseases. The firm's extracorporeal treatment is applicable for hard-to-cure blood-borne and neurologic diseases, such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. The company is also developing treatment for coronavirus disease of 2019 (Covid-19), obesity, such as high blood pressure, diabetes, heart disease, stroke, and cancer.
